Key Takeaways FOLD reported Q4 EPS of 10 cents, missing estimates, as revenues rose 24% Y/Y to $185.2M.Amicus saw Galafold sales rise 14% and Pombiliti plus Opfolda jump 51% Y/Y at constant exchange rates.BioMarin will acquire Amicus for $14.50 per share in a $4.8B cash deal set to close in Q2 2026.Amicus Therapeutics (FOLD) reported adjusted earnings of 10 cents per share for the fourth quarter of 2025, which missed the Zacks Consensus Estimate of 13 cents. The company had reported adjusted earnings of 9 c ...

PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold® (migalastat) in Fabry disease and POMBILITI® + OPFOLDA® (cipaglucosidase alfa plus miglustat) in late-onset Pompe disease. Data are being presented at the 22nd Annual WORLDSymposium™ 2026. “Amicus continues to advance the science and understanding of both Fabry and Pompe diseases, and we are proud to showcase new data for our me ...

Group 1 - BioMarin Pharmaceutical Inc. is set to acquire Amicus Therapeutics in an all-cash transaction valued at approximately $4.8 billion, with a share price of $14.50 per Amicus share [2][3] - The acquisition is expected to close in Q2 2026, pending regulatory clearances and stockholder approval [2] - This strategic move is aimed at stabilizing long-term cash flows and expanding BioMarin's leadership in rare diseases by adding two marketed therapies for lysosomal storage disorders, which generated a combined revenue of $599 million over the last four quarters [3] Group 2 - H.C. Wainwright raised BioMarin's price target to $60 from $55, maintaining a Neutral rating, indicating that Voxzogo will remain the primary driver of stock value until peak sales materialize in the 2030s [1][3] - The acquisition includes US rights to DMX-200, a Phase 3 investigational small molecule targeting focal segmental glomerulosclerosis, a rare kidney disease [3] - BioMarin develops and commercializes therapies for life-threatening rare diseases and medical conditions across various regions including the US, Europe, and Asia Pacific [4]

Core Viewpoint - BioMarin Pharmaceutical has agreed to acquire Amicus Therapeutics for $4.8 billion, enhancing its portfolio with therapies for lysosomal storage disorders [1] Group 1: Acquisition Details - BioMarin will pay $14.50 per share for Amicus, representing a 33% premium over Amicus' stock value of $10.89 on December 18 [1] - This acquisition is the largest in BioMarin's history and has resulted in a 17.71% increase in BioMarin's stock price, from $51.95 to $61.15 [2] Group 2: Acquired Therapies - The acquisition includes rights to Amicus' Fabry disease therapy, Galafold, which generated $458.1 million in 2024, an 18% increase from 2023 [2] - Galafold is the only FDA-approved chaperone therapy for Fabry disease and has market exclusivity until January 30, 2027, following a patent litigation with Teva Pharmaceuticals [3] - BioMarin will also acquire the FDA-approved Pompe disease combination therapy, Pombiliti plus Opfolda, which generated $22 million in 2024 [4][5] Group 3: Future Growth Strategy - BioMarin has been focusing on growth in the pharmaceutical sector, undergoing significant restructuring in 2024, which included laying off 225 employees [7] - The company has adopted a strong dealmaking strategy, signing 10 deals in 2025, the highest number since 2010 according to GlobalData's Pharmaceutical Intelligence Center [7] - BioMarin is also acquiring rights to the investigational oral small molecule DMX-200, currently in Phase III trials for focal segmental glomerulosclerosis [6]

Core Viewpoint - BioMarin Pharmaceutical Inc. has announced a definitive agreement to acquire Amicus Therapeutics for $14.50 per share in an all-cash transaction valued at approximately $4.8 billion, which is expected to enhance BioMarin's revenue growth and diversify its product portfolio in the rare disease market [2][3][4]. Group 1: Acquisition Details - The acquisition will add two marketed high-growth products, Galafold and Pombiliti + Opfolda, which generated combined revenues of $599 million over the past four quarters [1][4]. - The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close in the second quarter of 2026, pending regulatory clearances and stockholder approval [2][3]. - BioMarin intends to finance the acquisition through cash on hand and approximately $3.7 billion of non-convertible debt financing [8]. Group 2: Financial Impact - The acquisition is expected to be accretive to Non-GAAP Diluted Earnings Per Share (EPS) in the first 12 months post-close and substantially accretive beginning in 2027 [1][4][5]. - BioMarin is targeting a gross leverage of less than 2.5x within two years after the close of the transaction, demonstrating a commitment to deleveraging [5][8]. Group 3: Strategic Fit - The combination of BioMarin and Amicus is seen as a strategic fit due to both companies' dedication to transforming care for patients with rare diseases [3][4]. - The acquisition will strengthen BioMarin's commercial portfolio and provide opportunities to expand access to Galafold and Pombiliti + Opfolda across its global footprint [1][4][5]. Group 4: Product Information - Galafold is the first oral treatment for Fabry disease, while Pombiliti + Opfolda is a two-component therapy for Pompe disease, both targeting lysosomal storage disorders [4][15]. - Amicus also holds U.S. rights to DMX-200, an investigational small molecule for treating focal segmental glomerulosclerosis, which is in Phase 3 development [4].

Core Insights - Amicus Therapeutics is experiencing significant growth driven by its lead product, Galafold, which is crucial for the company's revenue generation [1][9] - Galafold is approved for treating Fabry disease and is available in multiple countries, including the US, EU, UK, and Japan [1] - The company has also made progress with its two-component therapy, Pombiliti + Opfolda, which is approved for late-onset Pompe disease [5] Financial Performance - In the first nine months of 2025, Galafold generated sales of $371.5 million, reflecting a year-over-year increase of approximately 12% [2][9] - The sales forecast for Galafold suggests a compound annual growth rate (CAGR) of 10.4% over the next three years [2] - Pombiliti + Opfolda achieved sales of $77.5 million during the same period, marking a significant year-over-year increase of 61.5% [5][9] Competitive Landscape - Amicus faces rising competition in the market for lysosomal storage disorders, particularly from established players like Sanofi and Takeda Pharmaceuticals [6][7] - The company’s reliance on Galafold for revenue generation is a concern, especially with increasing competition [6] Intellectual Property and Legal Developments - In October 2024, Amicus entered a licensing agreement with Teva Pharmaceuticals, preventing Teva from selling a generic version of Galafold in the US until January 2037 [4][9] Valuation and Market Performance - Amicus shares have increased by 5.7% year-to-date, compared to the industry growth of 20% [8] - The company's price-to-sales (P/S) ratio stands at 5.16, which is higher than the industry average of 2.49, although it is below its five-year mean of 9.06 [10] Earnings Estimates - The Zacks Consensus Estimate for 2025 earnings per share (EPS) has risen from 31 cents to 36 cents, while estimates for 2026 have decreased from 69 cents to 67 cents [11] Investment Rating - Amicus currently holds a Zacks Rank of 1 (Strong Buy) [15]

Financial Performance - Q3 2025 total revenue reached $169 million, a 17% increase[4,59] - Galafold revenue in Q3 2025 was $138.3 million[9,13] - Pombiliti + Opfolda revenue in Q3 2025 was $30.7 million, representing a 42% increase[26] - The company anticipates surpassing $1 billion in total revenue in FY 2028[5] - Non-GAAP net income for Q3 2025 was $54.2 million[59] Galafold Performance - Galafold revenue grew 15% in Q3 2025[11] - Approximately 2,730 individuals are currently being treated with Galafold[9] - Galafold holds a 69% share of treated amenable patients[9] Pombiliti + Opfolda Performance - Pombiliti + Opfolda revenue is expected to grow 50-65% in FY 2025[4,28] - The number of naïve starts for Pombiliti + Opfolda doubled in the first 9 months of 2025 compared to FY 2024[31]

Core Insights - Amicus Therapeutics' lead product, Galafold, is the primary revenue driver for the company, being the first oral precision medicine approved for Fabry disease treatment [1][2] - Galafold sales reached $233.1 million in the first half of 2025, reflecting an 11% year-over-year increase, with a projected CAGR of 11.7% over the next three years [2][9] - The company has secured strong patent protection for Galafold in the U.S. until 2038, following a licensing agreement with Teva Pharmaceuticals that prevents generic competition until January 2037 [3][4][9] Product Performance - Galafold has shown consistent sales growth since its launch, with label expansions and approvals in new regions contributing to its revenue increase [2][3] - The combination therapy Pombiliti + Opfolda for late-onset Pompe disease generated $46.8 million in sales during the first half of 2025, marking a 74% year-over-year increase [5] Market Dynamics - Amicus is heavily reliant on Galafold for revenue, which poses risks if regulatory challenges arise [6] - The company faces significant competition from established players in the lysosomal storage disorder market, including Sanofi and Takeda Pharmaceuticals, which market products for Fabry and Pompe diseases [7][8]

Core Insights - Amicus Therapeutics reported adjusted earnings of 1 cent per share for Q2 2025, missing the Zacks Consensus Estimate of 2 cents, compared to a loss of 6 cents per share in the same quarter last year [1][6] Financial Performance - Revenues for Q2 2025 totaled $154.7 million, representing a 22% year-over-year increase on a reported basis and an 18% increase at constant exchange rates, surpassing the Zacks Consensus Estimate of $148 million [2][6] - Galafold sales reached $128.9 million, up 12% year-over-year at constant exchange rates, although it fell short of the Zacks Consensus Estimate of $133 million [4][6] - Sales of the newly approved combination drug Pombiliti + Opfolda amounted to $25.8 million, exceeding both the Zacks Consensus Estimate of $24 million and the internal model estimate of $25 million [4][6] Growth Drivers - The revenue increase was attributed to higher sales from Galafold and additional revenues from Pombiliti + Opfolda, with ongoing studies aimed at expanding treatment labels for both Fabry and Pompe diseases [3][6] - The company maintained its 2025 revenue growth guidance of 15-22% at constant exchange rates, with Galafold expected to grow by 10-15% and Pombiliti + Opfolda by 50-65% [8] Operating Expenses and Cash Position - Adjusted operating expenses rose 56% to $127.8 million in Q2 2025, primarily due to a $30 million upfront payment for licensing rights to DMX-200 [7] - As of June 30, 2025, Amicus had cash, cash equivalents, and marketable securities totaling $231 million, down from $250.6 million as of March 31, 2025 [7] Future Outlook - The company expects to achieve positive GAAP net income in the second half of 2025 and aims to exceed $1 billion in total sales by 2028 [9] - Amicus has licensed exclusive rights for the commercialization of DMX-200, a potential first-in-class treatment for FSGS, with the pivotal phase III study on track for full enrollment by the end of 2025 [10]

Financial Performance - Q2 2025 total revenue reached $154.7 million, an 18% increase at CER (Constant Exchange Rates)[61] - Non-GAAP net income for Q2 2025 was $1.9 million[61] - The company expects to surpass $1 billion in total revenue in FY 2028[6] - The company reiterates FY 2025 total revenue growth guidance of 15% to 22% at CER[65,67] Product Performance - Galafold Q2 2025 revenue was $128.9 million, a 16% increase in reported sales growth[10] - The company anticipates Galafold revenue growth of 10% to 15% for FY 2025 at CER[4,65,67] - Pombiliti + Opfolda Q2 2025 revenue was $25.8 million, a 58% increase at CER[22] - The company anticipates Pombiliti + Opfolda revenue growth of 50% to 65% for FY 2025 at CER[5,25,65,67] Strategic Initiatives - The company acquired U S licensing of DMX-200 Phase 3 Program[4] - The company aims to deliver positive GAAP net income during H2 2025[65,67]